Safety and efficacy of radionuclide therapy with high-activity in-111 pentetreotide in patients with progressive neuroendocrine tumors

Ebrahim S. Delpassand, Jennifer Sims-Mourtada, Hitomi Saso, Ali Azhdarinia, Faramarz Ashoori, Farzad Torabi, Gregory Espenan, Warren H. Moore, Eugene Woltering, Lowell Anthony

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

The intent of this study was to evaluate the safety and efficacy of high-activity 111In-pentetreotide in patients with neuroendocrine tumors. Thirty-two patients with pentetreotide-avid neuroendocrine tumors received therapy from August 2005 to November 2006. Fourteen (14) patients received 1 treatment and 18 patients received 2 treatments. Patients were followed an average of 12.73 months (range 1.2-24.5). Seventeen (17) patients (53%) had grade I or II hematologic toxicities, and 1 patient had grade III thrombocytopenia. One patient had grade II liver toxicity, which appeared 4 weeks after therapy and resolved on week 5. No patient had renal toxicity. Of the patients who completed 2 treatment cycles, 2 of 18 patients had partial disease regression, and 16 of 18 patients with previously progressive disseminated neuroendocrine disease achieved stable disease by imaging criteria. A decrease in serum tumor markers was observed in 14 of 18 patients given 2 therapies. A clinical response was achieved in 84% of the patients. Upon interim analysis, median survival was approximately 13 months (range 1.2-24.5). These results show that high-activity 111In-pentetreotide therapy is effective in patients with progressive disseminated neuroendocrine tumors.

Original languageEnglish
Pages (from-to)292-300
Number of pages9
JournalCancer Biotherapy and Radiopharmaceuticals
Volume23
Issue number3
DOIs
StatePublished - Jun 1 2008

Keywords

  • Neuroendocrine tumors
  • Pentetreotide
  • Radionuclide therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Safety and efficacy of radionuclide therapy with high-activity in-111 pentetreotide in patients with progressive neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this